-

Bruker Corporation to Present at Upcoming Investor Conferences

BILLERICA, Mass.--(BUSINESS WIRE)--Bruker Corporation (Nasdaq: BRKR) announced today it will present at the following conferences:

2024 Jefferies Global Healthcare Conference, New York, NY
Thursday, June 6, 2024, at 7:30 a.m. Eastern Time
Frank Laukien, Chairman, President and Chief Executive Officer
Juergen Srega, President, Bruker CALID Group

45th Annual Goldman Sachs Global Healthcare Conference, Miami, FL
Wednesday, June 12, 2024, at 11:20 a.m. Eastern Time
Gerald Herman, Executive Vice President and Chief Financial Officer

Live audio webcasts of the presentations will be available on the Investor Relations section of the Company's website at https://ir.bruker.com. Replays of the presentations will be posted in the “Events & Presentations” section of the Bruker Corporation Investor Relations website after the event and will be available for at least 30 days following the presentations.

About Bruker Corporation – Leader of the Post-Genomic Era (Nasdaq: BRKR)

Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker’s high-performance scientific instruments and high-value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity, and customer success in post-genomic life science molecular and cell biology research, in applied and biopharma applications, in microscopy and nanoanalysis, as well as in industrial and cleantech research, and next-gen semiconductor metrology in support of AI. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit www.bruker.com.

Contacts

Justin Ward
Sr. Director, Investor Relations & Corporate Development
Bruker Corporation
T: +1 (978) 313-5800
E: Investor.Relations@bruker.com

Bruker Corporation

NASDAQ:BRKR

Release Versions
$Cashtags
Hashtags

Contacts

Justin Ward
Sr. Director, Investor Relations & Corporate Development
Bruker Corporation
T: +1 (978) 313-5800
E: Investor.Relations@bruker.com

Social Media Profiles
More News From Bruker Corporation

Bruker Accelerates the Future of Diagnostic and Prognostic Spatial Proteomics with the Launch of CellScape XR

ORLANDO, Fla.--(BUSINESS WIRE)--Bruker Corporation (Nasdaq: BRKR) announced the launch of CellScape™ XR, a next-generation spatial proteomics platform designed to advance the development of diagnostic and prognostic assays by delivering unprecedented quantitative performance, robustness, and flexibility. CellScape XR addresses a critical bottleneck in translational research by enabling high-throughput, reproducible spatial proteomics at a scale and rigor required for translational and clinical...

Bruker Expands Collaboration with Noetik to Advance Tissue Foundational Models for Translational and Therapeutic Applications

ORLANDO, Fla.--(BUSINESS WIRE)--Bruker Spatial Biology, a division of Bruker Corporation (Nasdaq: BRKR) announced today that it will expand its collaboration with Noetik Inc., following their prior study of more than 3500 patient samples with the CosMx® Spatial Molecular Imager (SMI). CosMx SMI powers Noetik's pre-training and scaling of bio-foundation models to perform complex genome-wide simulations of human cellular- and tissue-level biology to enable diverse therapeutics applications. “Noet...

Bruker Announces Major Advancements at AGBT to Enable Complete High-Fidelity Spatial Biology Across the Biological Spectrum

ORLANDO, Fla.--(BUSINESS WIRE)--Bruker Corporation (Nasdaq: BRKR) announced today significant portfolio advancements from Bruker Spatial Biology to be unveiled at the 2026 Advances in Genome Biology and Technology (AGBT) General Meeting. These updates highlight Bruker’s category leadership in spatial biology and its commitment to delivering best‑in‑class solutions across DNA, RNA, and protein. The Bruker Spatial Biology division will launch several new products, introduce expanded capabilities,...
Back to Newsroom